The Department of Endocrinology, 
Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective.
- Bharti Hospital, Karnal, Haryana, India.
- Centre for Diabetes and Endocrine Care, Srinagar, Jammu and Kashmir, India.
- Endocrine and Diabetes Centre, Visakhapatnam, Andhra Pradesh, India.
- Pondicherry Institute of Medical Sciences, Pondicherry, India.
- Diabetes & Endocrinology Super Specialty Center, Aligarh, Uttar Pradesh, India.
- Department of Cardiology, Jaipur Golden Hospital, Delhi, India.
- Diabetes Medicare Centre, Apollo Specialty Hospital, Chennai, Tamil Nadu, India.
- Diabetes Care and Research Centre, Patna, Bihar, India.
- Department of Endocrinology, Osmania Medical College, Hyderabad, Telangana, India.
- Department of Endocrinology, St. John's Hospital, Bengaluru, Karnataka, India.
- Department of Endocrinology, Institute of Post Graduate Medical Education & Research, Kolkata, West Bengal, India.
- Department of Endocrinology, St John's Medical College, Bengaluru, Karnataka, India.
- Department of Cardiology, Apollo Hospital, Mysore, Karnataka, India.
- Chellaram Diabetes Institute, Pune, Maharashtra, India.
- Department of Endocrinology, People's College of Medical Sciences, Bhopal, Madhya Pradesh, India.
- Vivekananda Institute of Medical Sciences, Kolkata, West Bengal, India.
- Department of Endocrinology, Apollo Excel Hospital, Guwahati, Assam, India.
- Department of Cardiology, N.R.S. Medical College, Kolkata, West Bengal, India.
- Department of Endocrinology, Fortis Hospital, Mohali, Chandigarh, India.
- Department of Endocrinology, Endocrine and Diabetes Clinic, Mumbai, Maharashtra, India.
- Department of Endocrinology, Endodiab Clinic, Calicut, Kerala, India.
- Mangalore Endodiab Clinic
- Department of Endocrinology, Diabetes & Metabolism A J Institute of Medical Sciences, Mangalore, Karnataka, India.
- Department of Endocrinology, Christian Medical College, Vellore, Tamil Nadu, India.
- Magna Centre for Obesity, Diabetes and Endocrinology, Hyderabad, Telangana. India.
- Heart Rhythm Clinic, Mumbai, Maharashtra, India.
- Department of Endocrinology, Gangaram Bansal Hospital, Sri Ganganagar, Rajasthan, India.
- Department of Endocrinology, S.M.S. Medical College and Hospital, Jaipur, Rajasthan, India.
Clinical medicine insights. Endocrinology and diabetes Vol. 17 · pp. 11795514231203911
PMID 38405679 DOI 10.1177/11795514231203911
Cite This Article
Sanjay Kalra, Abdul Hamid Zargar, G R Sridhar, Ashok Kumar Das, Jamal Ahmed, Jagdish Chander Mohan, G Vijayakumar, Ajay Kumar, Rakesh Kumar Sahay, Vageesh Ayer, Kaushik Pandit, Ganapathi Bantwal, Arun Srinivas, A G Unnikrishnan, Sushil Jindal, Saumitra Ray, Manash P Baruah, Kajal Ganguly, Sachin Mittal, Ameya Joshi, Joe George, Ganesh Hk, Nitin Kapoor, Santosh Ramakrishnan, Chetan Shah, Atul Dhingra, Balram Sharma. Expert eValuation of Efficacy and Rationality of Vildagliptin “EVER-Vilda”: An Indian Perspective. Clinical medicine insights. Endocrinology and diabetes. 2024;17:11795514231203911. doi:10.1177/11795514231203911
Abstract
Vildagliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor is effective in reducing HbA1c levels in patients with type 2 diabetes (T2DM) when administered as monotherapy, dual or triple combination therapy. In India, Vildagliptin is commonly prescribed in T2DM patients because it reduces mean amplitude of glycemic excursion (MAGE), has lower risk of hypoglycemia and is weight neutral. Early combination therapy with vildagliptin and metformin is effective and well-tolerated in patients with T2DM, regardless of age or ethnicity. In view of already existing data on vildagliptin and the latest emerging clinical evidence, a group of endocrinologists, diabetologists and cardiologists convened for an expert group meeting to discuss the role and various combinations of vildagliptin in T2DM management. This practical document aims to guide Physicians and Specialists regarding the different available strengths and formulations of vildagliptin for the initiation and intensification of T2DM therapy.
Keywords
- dpp-4 inhibitors
- hyperglycemia
- oral hypoglycemic agents
- type 2 diabetes mellitus
- vildagliptin
